Navigation Links
Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
Date:10/11/2011

ANAHEIM, Calif., Oct. 11, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2011 financial results on Tuesday, October 25, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and slide presentation via webcast on Tuesday, October 25, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the third quarter, as well as current corporate developments.  

Conference call details:Date:Tuesday, October 25, 2Time:4:30 p.m. ETDial-in (U.S.):877-941-1465Dial-in (International):480-629-9643Web cast:www.questcor.comTo access an audio replay of the call:

Replay (U.S.):800-406-7325Replay (International):303-590-303Replay Passcode:4480054About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
3. Questcor Provides Updated New Paid Prescription Trends
4. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
5. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
6. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
7. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
8. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
9. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
10. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
11. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 GenomeDx Biosciences today ... the American Society for Radiation Oncology (ASTRO) Annual ... Cancer Classifier, a genomic test capable of predicting ... and improve patient outcomes for prostate cancer patients ... a recently published study that demonstrates how Decipher ...
(Date:9/15/2014)...  Alere Inc. (NYSE: ALR ) (the ... toxicology, cardiology and diabetes products and services, today confirmed ... CEO Ron Zwanziger , filed a Schedule 13D ... a letter to Gregg J. Powers , Chairman ... in an effort to secure financing to make a ...
(Date:9/15/2014)... Sept. 15, 2014 /PRNewswire/ -  Pivotal Therapeutics Inc. ... pharmaceutical company with a focus on Omega-3 therapies ... that the Board of Directors approved the granting ... advisor at the close of business on Friday, September ... 1,000,000 common shares of the Company were granted ...
Breaking Medicine Technology:Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Alere Responds To Letter From Former Executives 2Pivotal Therapeutics Grants Incentive Stock Options 2
... STATEN ISLAND, N.Y., Feb. 28, 2011  A 67-year-old man ... his wife after wandering outside in near-freezing temperatures thanks to ... a watch-like EmSeeQ® wearable locator device. ... Marilyn, discovered him missing. He was located on Victory Boulevard, ...
... Corporation (Nasdaq: HSKA ; "Heska" or the ... Thursday, March 3rd, 2011.  The company,s presentation is scheduled ... Mountain Time) and is to be available to interested ... is to be available via live webcast and for ...
Cached Medicine Technology:Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 2Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 3Heska to Present Live, Online at RetailInvestorConferences.com 2
(Date:9/15/2014)... MONDAY, Sept. 15, 2014 (HealthDay News) -- U.S. heart ... an electrocardiogram (ECG) when evaluating young people for underlying ... The American Heart Association and the American College ... more detailed personal and family medical history along with ... genetic or congenital (existing from birth) risks for sudden ...
(Date:9/15/2014)... (PRWEB) September 16, 2014 “Canada ... market data on the Canada Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Female Sterilization Devices (Transcervical Sterilization Devices ... Rings) , Endometrial Ablation Devices (Thermal ...
(Date:9/15/2014)... Maureen Salamon HealthDay ... -- Pediatricians prescribe antibiotics about twice as often as ... infections, a new study indicates. More than 11 ... teens may be unnecessary, according to researchers from University ... use not only fails to eradicate children,s viral illnesses, ...
(Date:9/15/2014)... 15, 2014 As Colorado's historic ... its first full year, there are a variety ... in the evolution of its marketing and branding. ... taken by Denver's Kindman, one of the state's ... , Kindman has pioneered the first-ever branded and ...
(Date:9/15/2014)... Physicians and clinicians from around ... at the Lowes Coronado Bay Resort for the ... . This CME accredited medical conference ... healthcare professionals—about the nutritional science that overwhelmingly supports ... its proven ability to prevent, suspend and, often, ...
Breaking Medicine News(10 mins):Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 2Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 3Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 4Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 2Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 3
... the Netherlands have identified a chemical agent that may ... syndrome (BOS), or popcorn workers lung, a severe occupational ... an American plant that makes microwaveable popcorn. ... at a chemical plant that produced diacetyl (a key ...
... the way toward screening people at risk for lung ... researchers from the University of Colorado say. , The ... prevention, said researcher Wilbur A. Franklin, M.D., Professor of ... Our goal would be to develop screening techniques for ...
... the Board, SAN DIEGO, Aug. 30 ResMed ... of directors has unanimously approved a,succession plan for executive ... Gallahue will be promoted to Chief Executive Officer and,will ... succeed Dr. Peter,C. Farrell, 65. As of January 1, ...
... The United States,Government, through the U.S. Agency for ... million in equipment and technical,assistance to the Government ... country. This announcement follows the provision of an ... the Hellenic Red Cross for emergency,fire fighting equipment ...
... grants 1500 Caregivers, members of SEIU UHW-West and 121RN, ... and classification at hospital, BURBANK, Calif., Aug. 30 ... members of SEIU United Healthcare Workers -,West (UHW) and ... Providence St. Joseph Medical Center. The contract, which expires,Sept. ...
... Four-Star,General Barry McCaffrey (ret), former White House National Drug ... International,Affairs and a widely cited terrorism and drug policy ... Chair of a State Capitol rally for,recovery and treatment ... at,11:30. Also speaking will be California HHS Secretary ...
Cached Medicine News:Health News:Chemical culprit in 'popcorn worker's lung' identified 2Health News:New technique detects specific chromosomal damage, may indicate lung cancer risk 2Health News:ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008. 2Health News:Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract 2Health News:4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote 'Recovery Happens!' Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento 2
... EX accelerators are true ... Varian multileaf collimation and ... which enable you to ... computer-driven IMRT treatments, as ...
The Clinac 2100 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
The Clinac 6EX accelerator is a cost-effective choice. Configured for the latest treatment techniques, the Clinac 6EX has the tightest mechanical and dosimetric specifications for any single-energy m...
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
Medicine Products: